Optic pathway gliomas in neurofibromatosis-1: Controversies and recommendations

Robert Listernick, Rosalie E. Ferner, Grant T. Liu, David H. Gutmann*

*Corresponding author for this work

Research output: Contribution to journalReview article

365 Scopus citations

Abstract

Optic pathway glioma (OPG), seen in 15% to 20% of individuals with neurofibromatosis type 1 (NF1), account for significant morbidity in young children with NF1. Overwhelmingly a tumor of children younger than 7 years, OPG may present in individuals with NF1 at any age. Although many OPG may remain indolent and never cause signs or symptoms, others lead to vision loss, proptosis, or precocious puberty. Because the natural history and treatment of NF1-associated OPG is different from that of sporadic OPG in individuals without NF1, a task force composed of basic scientists and clinical researchers was assembled in 1997 to propose a set of guidelines for the diagnosis and management of NF1-associated OPG. This new review highlights advances in our understanding of the pathophysiology and clinical behavior of these tumors made over the last 10 years. Controversies in both the diagnosis and management of these tumors are examined. Finally, specific evidence-based recommendations are proposed for clinicians caring for children with NF1.

Original languageEnglish (US)
Pages (from-to)189-198
Number of pages10
JournalAnnals of neurology
Volume61
Issue number3
DOIs
StatePublished - Mar 2007

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Optic pathway gliomas in neurofibromatosis-1: Controversies and recommendations'. Together they form a unique fingerprint.

  • Cite this